Gene · 2145
EZH1: enhancer of zeste 1 polycomb repressive complex 2 subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. EZH1: enhancer of zeste 1 polycomb repressive complex 2 subunit. Genes, record 2145. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2145
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q92800 | Histone-lysine N-methyltransferase EZH1 | 747 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents35
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 45017 | Q92800 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 13299 | Q92800 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 15106 | Q92800 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14959 | Q92800 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 15106 | Q92800 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 13299 | Q92800 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 14959 | Q92800 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 14959 | Q92800 | Espacenet |
| US 12178854 B2 | 2024-12-31 | 1 | Q92800 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 14798 | Q92800 | Espacenet |
1 to 10 of 35
See all 35 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,102
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | EZH1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 25 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 5 | 2025 |
| R01CA199652 | Repression via Facultative Heterochromatin | 5 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 4 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 3 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 3 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,102Source NIH's project files
See all 1,102 nih grantsPapers1,378
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploiting an epigenetic resistance mechanism to PI3-kinase inhibition in leukemic stem cells. | Leukemia | 2026 | 42806054 | PubTator, text mining | PubMed |
| Biallelic EZH1 Nonsense Novel Variant in Two Siblings with Neurodevelopmental Disorder and Central Precocious Puberty: A Case Report from a Consanguineous Saudi Family. | Int J Mol Sci | 2026 | 42653090 | PubTator, text mining | PubMed |
| Thyroid cancer-associated EZH1 Q571R mutation drives chromatin compaction and H3K27me3 invasion into active chromatin. | Mol Cell | 2026 | 42398503 | PubTator, text mining | PubMed |
| Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2-Selective Small Molecule Inhibitor. | Adv Sci (Weinh) | 2026 | 42314051 | PubTator, text mining | PubMed |
| Impaired bone matrix turnover with selective small bone fragility in a child with TENT5A-associated osteogenesis imperfecta. | JBMR Plus | 2026 | 41908159 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine (m6A) regulates cell cycle progression in diffuse midline glioma (DMG) and confers sensitivity to FTO inhibition. | Cell Death Dis | 2026 | 41888518 | PubTator, text mining | PubMed |
| 3D Soft Hydrogels Induce Human Mesenchymal Stem Cells "Deep" Quiescence. | Adv Healthc Mater | 2026 | 41834288 | PubTator, text mining | PubMed |
| Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAFV600E Mutant A375 Melanoma Cells. | Oncol Res | 2026 | 41799498 | PubTator, text mining | PubMed |
| Circular RNAs in sepsis-induced acute lung injury: emerging mechanisms and therapeutic potential. | Front Immunol | 2026 | 41789098 | PubTator, text mining | PubMed |
| Impact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules: an Institutional Experience. | Endocr Pathol | 2026 | 41784850 | PubTator, text mining | PubMed |
1 to 10 of 1,378
See all 1,378 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2145
GET https://conductscience.org/api/genes/v1/2145/patents?page=2